Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$32.76 - $39.56 $25.6 Million - $30.9 Million
781,858 Added 47.8%
2,417,584 $84.5 Million
Q4 2023

Feb 14, 2024

BUY
$14.5 - $38.0 $274,847 - $720,290
18,955 Added 1.17%
1,635,726 $62.2 Million
Q3 2023

Nov 14, 2023

SELL
$15.75 - $26.31 $3.16 Million - $5.28 Million
-200,645 Reduced 11.04%
1,616,771 $29.7 Million
Q2 2023

Aug 14, 2023

SELL
$16.96 - $27.82 $4.39 Million - $7.19 Million
-258,574 Reduced 12.46%
1,817,416 $47.2 Million
Q1 2023

May 15, 2023

SELL
$18.45 - $27.14 $7.95 Million - $11.7 Million
-430,998 Reduced 17.19%
2,075,990 $39.2 Million
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $9.42 Million - $15.6 Million
466,934 Added 22.89%
2,506,988 $61.8 Million
Q3 2022

Nov 15, 2022

BUY
$11.58 - $24.73 $17.5 Million - $37.3 Million
1,506,986 Added 282.7%
2,040,054 $36.6 Million
Q2 2022

Aug 15, 2022

SELL
$8.52 - $25.26 $9.06 Million - $26.9 Million
-1,063,027 Reduced 66.6%
533,068 $6.05 Million
Q1 2022

May 16, 2022

BUY
$19.89 - $43.18 $13.7 Million - $29.6 Million
686,587 Added 75.49%
1,596,095 $35.6 Million
Q4 2021

Feb 14, 2022

BUY
$26.75 - $46.02 $10.6 Million - $18.2 Million
396,256 Added 77.2%
909,508 $39.7 Million
Q3 2021

Nov 15, 2021

BUY
$25.18 - $37.81 $2.12 Million - $3.18 Million
84,025 Added 19.58%
513,252 $17.1 Million
Q2 2021

Aug 16, 2021

BUY
$14.69 - $27.52 $3.95 Million - $7.41 Million
269,220 Added 168.26%
429,227 $11.8 Million
Q1 2021

May 17, 2021

BUY
$16.27 - $41.26 $447,099 - $1.13 Million
27,480 Added 20.74%
160,007 $3.21 Million
Q4 2020

Feb 16, 2021

BUY
$15.96 - $50.0 $2.12 Million - $6.63 Million
132,527 New
132,527 $4.37 Million

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.